562 related articles for article (PubMed ID: 29161297)
1. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
[TBL] [Abstract][Full Text] [Related]
2. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic and stratified value of adrenomedullin in community acquired pneumonia patients in emergency department].
Chen Y; Li C
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Feb; 26(2):115-9. PubMed ID: 24524403
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
[TBL] [Abstract][Full Text] [Related]
5. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
[TBL] [Abstract][Full Text] [Related]
7. Reliability of Pro-adrenomedullin and Interleukin 1β in Predicting Severity of Community-Acquired Pneumonia in Pediatric Patients.
Korkmaz MF; Güzel A; Açıkgöz M; Okuyucu A; Alaçam H
Ann Clin Lab Sci; 2018 Jan; 48(1):81-89. PubMed ID: 29531001
[TBL] [Abstract][Full Text] [Related]
8. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
[TBL] [Abstract][Full Text] [Related]
9. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
[TBL] [Abstract][Full Text] [Related]
10. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
[TBL] [Abstract][Full Text] [Related]
11. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study.
Sardà Sánchez M; Hernández JC; Hernández-Bou S; Teruel GC; Rodríguez JV; Cubells CL
BMC Res Notes; 2012 Jul; 5():363. PubMed ID: 22818355
[TBL] [Abstract][Full Text] [Related]
12. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification and prediction value of procalcitonin and clinical severity scores for community-acquired pneumonia in ED.
Zhou H; Guo S; Lan T; Ma S; Zhang F; Zhao Z
Am J Emerg Med; 2018 Dec; 36(12):2155-2160. PubMed ID: 29691103
[TBL] [Abstract][Full Text] [Related]
14. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study.
Alan M; Grolimund E; Kutz A; Christ-Crain M; Thomann R; Falconnier C; Hoess C; Henzen C; Zimmerli W; Mueller B; Schuetz P;
J Intern Med; 2015 Aug; 278(2):174-84. PubMed ID: 25529395
[TBL] [Abstract][Full Text] [Related]
15. Do N-terminal pro-brain natriuretic peptide levels determine the prognosis of community acquired pneumonia?
Akpınar EE; Hoşgün D; Akpınar S; Ateş C; Baha A; Gülensoy ES; Ogan N
J Bras Pneumol; 2019 Aug; 45(4):e20180417. PubMed ID: 31411279
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
Liu D; Xie L; Zhao H; Liu X; Cao J
BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
[TBL] [Abstract][Full Text] [Related]
18. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections.
Schuetz P; Wolbers M; Christ-Crain M; Thomann R; Falconnier C; Widmer I; Neidert S; Fricker T; Blum C; Schild U; Morgenthaler NG; Schoenenberger R; Henzen C; Bregenzer T; Hoess C; Krause M; Bucher HC; Zimmerli W; Mueller B;
Crit Care; 2010; 14(3):R106. PubMed ID: 20529344
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia.
Nowak A; Breidthardt T; Christ-Crain M; Bingisser R; Meune C; Tanglay Y; Heinisch C; Reiter M; Drexler B; Arenja N; Twerenbold R; Stolz D; Tamm M; Müller B; Müller C
Chest; 2012 Apr; 141(4):974-982. PubMed ID: 22135381
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of procalcitonin in community-acquired pneumonia.
Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
